Kits Eyecare Reports Record Preliminary Q4 and Full 2025 Financial Results

Published on January 8, 2026
VANCOUVER, British Columbia—Kits Eyecare Ltd. (TSX: KITS), a leading vertically integrated eyecare provider, has reported select preliminary unaudited financial results for its fourth quarter and full year ended December 31, 2025. Key highlights include a 20 percent increase in Q4 revenue year-over-year to approximately $53.9 million, as well as record glasses revenue for Q4 at $8.7 million, up 33 percent compared with the previous year. The company also reported its full year 2025 revenue has grown 27 percent year-over-year to $202.5 million.
Continue reading on website
Other news

Outlook Therapeutics Appoints Laura Cantrell as VP of Corporate Strategy and Business Development

January 8, 2026
ISELIN, N.J.—Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of retinal diseases, announced it has appointed Laura Cantrell as vice president of corporate strategy and business development, effective immediately. In this role, Cantrell will be responsible for leading Outlook Therapeutics’ business de

Alcon Terminates Agreement to Acquire STAAR Surgical, Looks to Product Launches in 2026

January 8, 2026
NEWARK, N.J.—Alcon (SIX/NYSE: ALC), a global leader in eyecare, announced on Tuesday night the termination of its definitive merger agreement with STAAR Surgical Company (NASDAQ: STAA). The move followed a STAAR shareholder vote held early on Tuesday that failed to produce sufficient support for the proposed merger, valued at approximately $1.6 billion, as reported yesterday in VMAIL. Prior to Alc